The abstract is read at the publisher; the summary is JClub's.
A Translational Liver Cancer (TLC) Consortium framework defines four phases for developing, validating, and implementing hepatocellular cancer risk stratification models, from internal testing to impact evaluation.
- Why it matters: Guidelines recommend surveillance for cirrhosis and chronic HBV with added risk factors, but HCC incidence differs across groups. Existing models in cirrhosis are limited, leaving gaps in how to develop, validate, and assess real-world impact.
- What they did: The TLC convened clinicians, scientists, biostatisticians, and technology experts across the United States, Asia, and Europe to outline a phased process: phase 1 internal validation, phase 2 decision rules, phase 3 external validation, and phase 4 impact evaluation. It also issued recommendations to improve rigor for HCC risk stratification development and validation.
- The result: The framework provides best-practice steps to support guideline and regulatory endorsement and to guide implementation of HCC risk stratification in clinical practice.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.